Translational strategies to develop clinically safe and effective immune cell engagers
24 Sep 2024
Muir Woods
Translational Research
- Ways to determine FiH dose for oncology trials with immune cell engaging multi-specific antibodies
- Approaches for preclinical efficacy of combination therapies
- Have you worked on molecules which do not have an ideal in vivo efficacy/safety model? What are the additional hurdles to consider in such scenarios?
